Pablo Llerena

机构：Thomas Jefferson University, Thomas Jefferson University Hospital, Universidad de Las Américas, Sidney Kimmel Cancer Center, Instituto Nacional de Biodiversidad, SOLCA Núcleo de Quito, Universidad San Francisco de Quito · ORCID：0009-0008-1507-9723

发表论文 70 篇 · 总被引 117 次 · h-index 7

代表论文

• Improved survival with elevated BMI following immune checkpoint inhibition across various solid tumor cancer types (2025 · Cancer · 被引 17)
• Mortality in Cancer Patients with Septic Shock in Intensive Care: Systematic Review and Meta-Analysis (2025 · Journal of Intensive Care Medicine · 被引 8)
• Extracellular Matrix–MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC (2025 · Clinical Cancer Research · 被引 6)
• Pathologic Treatment Effect and Survival in HPV-Negative HNSCC Following Neoadjuvant Nivolumab (2025 · JAMA Otolaryngology–Head & Neck Surgery · 被引 5)
• Flow‐Through Flaps as a Robust Method for Advanced Free Flap Reconstruction in the Head and Neck: A Multi‐Institutional Experience (2025 · Head & Neck · 被引 4)
• Neoadjuvant Nivolumab plus Carboplatin and Paclitaxel in Patients with Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck: A Phase II, Single-Arm Trial (2025 · Clinical Cancer Research · 被引 2)